Effect of Rosuvastatin Therapy on Biomarkers of Inflammation and Immune Activation in People With Human Immunodeficiency Virus at Intermediate Cardiovascular Risk. (22nd December 2020)

• Record Type: Journal Article
• Authors: Hearps, Anna C; Angelovich, Thomas A; Trevillyan, Janine M; Wong, Michelle E; Calmy, Alexandra; Hoy, Jennifer F; Jaworowski, Anthony
• Is Part Of: Journal of infectious diseases. Volume 224:Number 4(2021)
• Page Start: 667
• Page End: 672
• Publication Date: 2020-12-22
• Subjects: HIV -- rosuvastatin -- chronic inflammation -- monocytes -- immune activation -- cardiovascular disease; Communicable diseases -- Periodicals; Diseases -- Causes and theories of causation -- Periodicals; Medicine -- Periodicals; Communicable Diseases -- Periodicals; Electronic journals; 616.9
• DOI: 10.1093/infdis/jiaa775
• Languages: English
• ISSNs: 0022-1899

Abstract

Abstract: Background: Statins may help prevent cardiovascular disease (CVD) in people with human immunodeficiency virus (PWH) with chronic inflammation owing to their pleotropic lipid-lowering and anti-inflammatory properties. Methods: The impact of 48 weeks of rosuvastatin therapy on inflammation and immune activation in a double-blind, placebo-controlled trial in PWH at moderate cardiovascular disease risk was assessed. Results: Rosuvastatin did not alter plasma levels of interleukin 6, soluble tumor necrosis factor receptor type 2, CXCL10, soluble CD14, or soluble vascular cellular adhesion molecule 1 ( P ≥ .1 for all). Proportions of CD16 + monocyte subsets were increased in PWH receiving rosuvastatin. Conclusions: The potential benefits of statin use in PWH with normal lipid levels requires further clinical outcome research. Abstract : In a cohort of people with human immunodeficiency virus at intermediate risk of cardiovascular disease, rosuvastatin therapy did not improve markers of inflammation or immune/endothelial activation. The use of statins in those with normal lipid levels should be carefully considered.